Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 15/20 | 0.87 |
| ▸ | LMNA | P02545 | 2/20 | 0.87 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.80 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | USP2 | O75604 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7324222 | 1.00 | ACE (0.87) | ACELMNASMN1; SMN2ABCB11MEN1 | |
| Hydrochloric Acid SCHEMBL6414637 | 0.99 | ACE (0.85) | ACELMNASMN1; SMN2ABCB11MEN1 | |
| Hydrochloric Acid SCHEMBL7333419 | 0.99 | ACE (0.85) | ACELMNASMN1; SMN2ABCB11MEN1 | |
| Maleic Acid SCHEMBL7258070 | 0.95 | SMN1; SMN2 (0.88) | ACELMNASMN1; SMN2ABCB11MEN1 | |
| SCHEMBL9863830 | 0.95 | ACE (0.82) | ACELMNASMN1; SMN2ABCB11MEN1 | |
| SCHEMBL10802722 | 0.95 | ACE (0.82) | ACELMNASMN1; SMN2ABCB11MEN1 | |
| SCHEMBL16364868 | 0.95 | ACE (0.85) | ACELMNASMN1; SMN2ABCB11MEN1 | |
| Enalaprilat Anhydrous SCHEMBL7258975 | 0.95 | ACE (0.88) | ACELMNASMN1; SMN2ABCB11MEN1 | |
| SCHEMBL3126925 | 0.94 | ACE (0.80) | ACELMNASMN1; SMN2ABCB11 | |
| Enalapril SCHEMBL6159149 | 0.93 | ACE (1.00) | ACELMNASMN1; SMN2ABCB11MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050100589-A1 | Transdermal administration of ace inhibitors | NOVEN PHARMACEUTICALS, INC. | 2005-05-12 | — | — | US | claimed |
| US-6805878-B2 | TOPICAL ADMINISTERING ENALAPRILAT | NOVEN PHARMACEUTICALS, INC. | 2004-10-19 | — | — | US | claimed |
| US-20030064933-A1 | Transdermal administration of ACE inhibitors | NOVEN PHARMACEUTICALS, INC. | 2003-04-03 | — | — | US | claimed |
| WO-2003022270-A1 | TRANSDERMAL ADMINISTRATION OF AN ENALAPRIL ESTER | NOVEN PHARMACEUTICALS, INC. (US) | 2003-03-20 | — | — | WO | claimed |
| EP-0079521-A1 | Process for preparation of carboxyalkyldipeptide derivatives | MERCK & CO. INC. (US) | 1983-05-25 | — | — | EP | claimed |
| EP-2537534-B1 | Esters of (1S,9S)-9-[[(1S)-1-carboxy-3-phenylpropyl]amino]octahydro-10-oxo-6H-pyridazino[1,2-a][1,2]diazepine-1-carboxylic acid and their therapeutic use. | HEXAL AG (DE) | 2014-12-17 | — | — | EP | disclosed |
| US-8785431-B2 | Prodrugs of (1S,9S)-9-[[(1S)-1-carboxy-3-phenylpropyl]amino]octahydro-10-oxo-6H-pyridazino[1,2-a][1,2]diazepine-1-carboxylic acid and their use in transdermal therapeutic systems | HEXAL AG (DE) | 2014-07-22 | — | — | US | disclosed |
| US-20140147477-A1 | PRODRUGS OF (1S,9S)-9-[[(1S)-1-CARBOXY-3-PHENYLPROPYL]AMINO]OCTAHYDRO-10-OXO-6H-PYRIDAZINO[1,2-A][1,2]DIAZEPINE-1-CARBOXYLIC ACID AND THEIR USE IN TRANSDERMAL THERAPEUTIC SYSTEMS | HEXAL AG (DE) | 2014-05-29 | — | — | US | disclosed |
| WO-2012175554-A1 | PRODRUGS OF (1S,9S)-9-[[(1S)-1-CARBOXY-3-PHENYLPROPYL]AMINO]OCTAHYDRO-10-OXO-6H-PYRIDAZINO[1,2-A][1,2]DIAZEPINE-1-CARBOXYLIC ACID AND THEIR USE IN TRANSDERMAL THERAPEUTIC SYSTEMS | HEXAL AG (DE) | 2012-12-27 | — | — | WO | disclosed |
| EP-2537534-A1 | Prodrugs of (1S,9S)-9-[[(1S)-1-carboxy-3-phenylpropyl]amino]octahydro-10-oxo-6H-pyridazino[1,2-a][1,2]diazepine-1-carboxylic acid and their use in transdermal therapeutic systems | Hexal AG (DE) | 2012-12-26 | — | — | EP | disclosed |
| US-20050100589-A1 | Transdermal administration of ace inhibitors | NOVEN PHARMACEUTICALS, INC. | 2005-05-12 | — | — | US | disclosed |
| US-20050100589-A1 | Transdermal administration of ace inhibitors | NOVEN PHARMACEUTICALS, INC. | 2005-05-12 | — | — | US | disclosed |
| US-6805878-B2 | TOPICAL ADMINISTERING ENALAPRILAT | NOVEN PHARMACEUTICALS, INC. | 2004-10-19 | — | — | US | disclosed |
| US-6805878-B2 | TOPICAL ADMINISTERING ENALAPRILAT | NOVEN PHARMACEUTICALS, INC. | 2004-10-19 | — | — | US | disclosed |
| US-20030064933-A1 | Transdermal administration of ACE inhibitors | NOVEN PHARMACEUTICALS, INC. | 2003-04-03 | — | — | US | disclosed |
| US-20030064933-A1 | Transdermal administration of ACE inhibitors | NOVEN PHARMACEUTICALS, INC. | 2003-04-03 | — | — | US | disclosed |
| WO-2003022270-A1 | TRANSDERMAL ADMINISTRATION OF AN ENALAPRIL ESTER | NOVEN PHARMACEUTICALS, INC. (US) | 2003-03-20 | — | — | WO | disclosed |
| WO-2003022270-A1 | TRANSDERMAL ADMINISTRATION OF AN ENALAPRIL ESTER | NOVEN PHARMACEUTICALS, INC. (US) | 2003-03-20 | — | — | WO | disclosed |
| EP-0079521-A1 | Process for preparation of carboxyalkyldipeptide derivatives | MERCK & CO. INC. (US) | 1983-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140147477-A1 | PRODRUGS OF (1S,9S)-9-[[(1S)-1-CARBOXY-3-PHENYLPROPYL]AMINO]OCTAHYDRO-10-OXO-6H-PYRIDAZINO[1,2-A][1,2]DIAZEPINE-1-CARBOXYLIC ACID AND THEIR USE IN TRANSDERMAL THERAPEUTIC SYSTEMS | DPP9, CYP2C9, DPP7 | ACE 10/4885LMNA 2972/4885SMN1; SMN2 2790/4885 |
| US-20030064933-A1 | Transdermal administration of ACE inhibitors | ACE, AGT, AGTR1 | ACE 1/4885LMNA 1238/4885SMN1; SMN2 2110/4885 |
| US-20050100589-A1 | Transdermal administration of ace inhibitors | ACE, AGT, AGTR1 | ACE 1/4885LMNA 1238/4885SMN1; SMN2 2110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.